Jim Simons Eiger Bio Pharmaceuticals, Inc. Transaction History

Renaissance Technologies LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$0.21 - $0.43 $72,284 - $148,010	344,210 New	344,210 $77,000
Q2 2023 Aug 11, 2023	SELL	$0.55 - $1.26 $217,790 - $498,937	-395,982 Reduced 84.67%	71,700 $50,000
Q1 2023 May 12, 2023	BUY	$0.89 - $2.52 $142,739 - $404,162	160,382 Added 52.19%	467,682 $419,000
Q4 2022 Feb 13, 2023	BUY	$1.02 - $7.48 $313,446 - $2.3 Million	307,300 New	307,300 $363,000
Q4 2021 Feb 11, 2022	SELL	$5.12 - $8.19 $680,366 - $1.09 Million	-132,884 Closed	0 $0

Q3 2021 Nov 12, 2021	BUY	$6.68 - $9.1 $663,050 - $903,256	99,259 Added 295.19%	132,884 $888,000
Q2 2021 Aug 13, 2021	SELL	$7.82 - $9.23 $572,885 - $676,180	-73,259 Reduced 68.54%	33,625 $286,000
Q1 2021 May 13, 2021	BUY	$8.44 - $12.66 $902,100 - $1.35 Million	106,884 New	106,884 $946,000
Q2 2020 Aug 13, 2020	SELL	$5.4 - $13.37 $1.46 Million - $3.63 Million	-271,184 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$4.91 - $14.7 $628,750 - $1.88 Million	128,055 Added 89.47%	271,184 $1.84 Million
Q4 2019 Feb 13, 2020	SELL	$9.77 - $15.66 $568,614 - $911,412	-58,200 Reduced 28.91%	143,129 $2.13 Million
Q3 2019 Nov 13, 2019	SELL	$9.59 - $12.0 $932,953 - $1.17 Million	-97,284 Reduced 32.58%	201,329 $2.06 Million
Q2 2019 Aug 12, 2019	BUY	$9.54 - $14.96 $187,785 - $294,472	19,684 Added 7.06%	298,613 $3.17 Million
Q1 2019 May 14, 2019	BUY	$10.31 - $14.38 $265,998 - $371,004	25,800 Added 10.19%	278,929 $3.9 Million
Q4 2018 Feb 13, 2019	BUY	$8.63 - $12.4 $2.18 Million - $3.14 Million	253,129 New	253,129 $2.57 Million

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $556M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.